

Study: ENGOT-en15 / KEYNOTE-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting. (KEYNOTE-C93/GOG-3064/ENGOT-en15)

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
FI	Firenze	Ospedale Careggi	Lorenzo Antonuzzo	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
PD	Padova	Istituto Oncologico Veneto	Giulia Tasca	
TO	Torino	Ospedale Sant'Anna	Paolo Zola	R

***MaNGO Principal Investigator**

R: backup site